Globalworld globe
United Kingdom
North America
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox: USA update

Aug 29, 2018Cathy WilsonNews

29 August 2018

ASX Announcement

Penthrox: USA update

Medical Developments International Limited (ASX: MVP) advise that it has received correspondence from the USA Food & Drug Administration (?FDA?) in relation to its Investigative New Drug (?IND?) application to have Penthrox approved for sale in the United States of America.

For the full release, please click on the link:?Penthrox USA Update

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

  • EU Transition and Trading Update

    3 December 2020 ASX ANNOU...

  • MVP Board Re-organisation

    3 December 2020 ASX ANNOU...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.